Eledon Pharmaceuticals (ELDN) Competitors $5.30 +0.65 (+13.98%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ELDN vs. NEOS, MLND, ARCT, GLUE, SAGE, VERV, KALV, LRMR, CGC, and SIGAShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Neos Therapeutics (NEOS), Millendo Therapeutics (MLND), Arcturus Therapeutics (ARCT), Monte Rosa Therapeutics (GLUE), Sage Therapeutics (SAGE), Verve Therapeutics (VERV), KalVista Pharmaceuticals (KALV), Larimar Therapeutics (LRMR), Canopy Growth (CGC), and SIGA Technologies (SIGA). These companies are all part of the "medical" sector. Eledon Pharmaceuticals vs. Neos Therapeutics Millendo Therapeutics Arcturus Therapeutics Monte Rosa Therapeutics Sage Therapeutics Verve Therapeutics KalVista Pharmaceuticals Larimar Therapeutics Canopy Growth SIGA Technologies Neos Therapeutics (NASDAQ:NEOS) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Does the media prefer NEOS or ELDN? In the previous week, Eledon Pharmaceuticals had 7 more articles in the media than Neos Therapeutics. MarketBeat recorded 8 mentions for Eledon Pharmaceuticals and 1 mentions for Neos Therapeutics. Eledon Pharmaceuticals' average media sentiment score of 0.59 beat Neos Therapeutics' score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eledon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend NEOS or ELDN? Eledon Pharmaceuticals has a consensus target price of $16.00, suggesting a potential upside of 201.89%. Given Eledon Pharmaceuticals' higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Neos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AEledon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in NEOS or ELDN? 33.1% of Neos Therapeutics shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 3.8% of Neos Therapeutics shares are held by company insiders. Comparatively, 11.7% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings & valuation, NEOS or ELDN? Neos Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Neos Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeos Therapeutics$64.65M0.89-$16.90M-$0.34-3.38Eledon PharmaceuticalsN/AN/A-$116.54M-$2.04-2.60 Does the MarketBeat Community prefer NEOS or ELDN? Neos Therapeutics received 474 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 72.22% of users gave Eledon Pharmaceuticals an outperform vote while only 63.94% of users gave Neos Therapeutics an outperform vote. CompanyUnderperformOutperformNeos TherapeuticsOutperform Votes50063.94% Underperform Votes28236.06% Eledon PharmaceuticalsOutperform Votes2672.22% Underperform Votes1027.78% Is NEOS or ELDN more profitable? Eledon Pharmaceuticals has a net margin of 0.00% compared to Neos Therapeutics' net margin of -38.35%. Neos Therapeutics' return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neos Therapeutics-38.35% N/A -28.46% Eledon Pharmaceuticals N/A -233.17%-45.44% Which has more risk and volatility, NEOS or ELDN? Neos Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. SummaryEledon Pharmaceuticals beats Neos Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$210.20M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-2.609.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book17.675.324.665.02Net Income-$116.54M$153.56M$119.06M$225.46M7 Day Performance56.34%0.11%0.80%0.37%1 Month Performance111.16%15.22%5.65%3.57%1 Year Performance338.02%41.14%36.76%29.44% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals3.1811 of 5 stars$5.30+14.0%$16.00+201.9%+292.6%$210.20MN/A-2.6010Gap UpNEOSNeos TherapeuticsN/A$1.15flatN/A+0.0%$57.22M$64.65M-2.61213Analyst ForecastNews CoverageHigh Trading VolumeMLNDMillendo TherapeuticsN/A$1.09+2.8%N/A-75.4%$20.76MN/A0.0012High Trading VolumeARCTArcturus Therapeutics2.6045 of 5 stars$19.43+2.5%$71.40+267.5%-4.1%$523.29M$147.03M-7.56180Upcoming EarningsNews CoverageGap UpGLUEMonte Rosa Therapeutics2.3295 of 5 stars$10.35+111.7%$14.67+41.7%+160.2%$522.80M$5.76M-4.6290Insider SellingAnalyst RevisionHigh Trading VolumeSAGESage Therapeutics4.3322 of 5 stars$8.53+6.5%$13.76+61.4%-69.3%$513.35M$97.24M-1.15690Earnings ReportAnalyst ForecastAnalyst RevisionVERVVerve Therapeutics2.3276 of 5 stars$6.03+1.0%$26.00+331.2%-49.5%$510.26M$11.76M-2.33110Upcoming EarningsKALVKalVista Pharmaceuticals3.3891 of 5 stars$12.08+3.4%$26.00+115.2%+21.0%$509.63MN/A-3.42150LRMRLarimar Therapeutics2.8618 of 5 stars$7.94-0.9%$20.43+157.3%+169.7%$506.65MN/A-7.0930Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCGCCanopy Growth1.337 of 5 stars$5.34-1.8%$3.50-34.5%-12.2%$501.21M$220.27M-0.761,029Upcoming EarningsShort Interest ↑Positive NewsGap UpSIGASIGA Technologies2.7842 of 5 stars$6.97+3.0%N/A+42.5%$497.45M$139.92M5.9640Upcoming EarningsOptions Volume Related Companies and Tools Related Companies NEOS Competitors MLND Competitors ARCT Competitors GLUE Competitors SAGE Competitors VERV Competitors KALV Competitors LRMR Competitors CGC Competitors SIGA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELDN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
